National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 632678

History of Changes from the VAERS Wayback Machine

First Appeared on 5/14/2016

VAERS ID: 632678
VAERS Form:
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 9/14/2017

VAERS ID: 632678 Before After
VAERS Form:(blank) 1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / - UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 2/14/2018

VAERS ID: 632678 Before After
VAERS Form:1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 6/14/2018

VAERS ID: 632678 Before After
VAERS Form:1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 8/14/2018

VAERS ID: 632678 Before After
VAERS Form:1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 9/14/2018

VAERS ID: 632678 Before After
VAERS Form:1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.


Changed on 10/14/2018

VAERS ID: 632678 Before After
VAERS Form:1
Age:
Sex:Unknown
Location:Unknown
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted:2016-04-22
Entered:2016-04-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other      Purchased by: Other
Symptoms: Death, Premature menopause

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': WAES1604USA013248

Write-up: This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender. The patients'' concurrent conditions and medical history were not provided. The reporter read in an article online that, on unspecified dates, an unspecified number of patients were vaccinated with GARDASIL (lot number, expiry date, dose, route and anatomical site of injection were not reported). Concomitant therapies were not provided. The article reported that an unspecified number of patients developed premature ovarian failure an unspecified time after receiving GARDASIL. Additionally, the article mentioned that an unspecified number of patients passed away on unknown dates, on an unspecified time after receiving GARDASIL. It was unspecified if the patients that passed away were the same patients that developed premature ovarian failure. It was unknown if an autopsy was performed. At the time of reporting, the outcome of premature ovarian failure was unknown. The reporter did not provide a causality assessment between the reported events and the GARDASIL. The cause of death was not mentioned. Additional information is not expected, as the reporting physician did not allow further contact for follow-up.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=632678&WAYBACKHISTORY=ON


Copyright © 2019 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166